menu search

Monte rosa therapeutics announces $25 million registered direct offering, priced at- the-market under nasdaq rules

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molec...

October 26, 2023, 8:30 pm

Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progress...

October 22, 2023, 11:00 am

Arvinas and pfizer announce upcoming vepdegestrant (arv-471) poster presentation at esmo congress 2023

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will p...

October 15, 2023, 10:05 pm

Foghorn therapeutics to present clinical and pre-clinical data from multiple programs across its diverse pipeline at aacr-nci-eortc international conference

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a ne...

October 4, 2023, 8:00 am

Monte rosa therapeutics appoints dr. anthony m. manning to board of directors

BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molec...

July 26, 2023, 11:30 am

C4 therapeutics announces fda clearance of investigational new drug application for cft8919, an orally bioavailable bidac™ degrader targeting egfr l858r for non-small cell lung cancer

WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated ...

July 5, 2023, 11:00 am

Nurix: still promising, but no new development except gilead licensing asset

In my last article, I said I liked Nurix, a protein degrader company. Since then, not much has happened...

June 26, 2023, 7:07 pm

Nurix therapeutics presents data from studies of its targeted protein degraders in b cell malignancies and initiates expansion of nx-2127 phase 1b trial in diffuse large b cell lymphoma and mantle cel

Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete ...

June 14, 2023, 11:00 am

Kymera therapeutics’ stat3 degrader kt-333 and irakimid degrader kt-413 demonstrate desired target knockdown and safety with continued dose escalation in ongoing phase i clinical trials

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associ...

June 14, 2023, 6:30 am

Kymera therapeutics announces updated clinical data from the phase 1 trials of stat3 degrader kt-333 and irakimid degrader kt-413

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...

June 9, 2023, 10:00 pm

Venezuela's oil exports drop as heavy crude processing sags, stocks drain

Venezuela's oil exports fell 14% in May from the previous month as crude upgraders at its main oil regi...

June 2, 2023, 12:19 pm

Monte rosa therapeutics announces first quarter 2023 financial results and provides corporate update

On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023 Cash runway into 2025...

May 11, 2023, 11:30 am

Olema oncology announces upcoming poster presentation at the 2023 esmo breast cancer annual congress

SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage bio...

May 8, 2023, 11:06 am

Marketgrader welcomes fintech and software entrepreneurs rob foregger and jim macintyre as strategic partners

New partnership will help accelerate Marketgrader’s mission to become the leading provider of next-ge...

April 19, 2023, 3:25 pm

Kymera therapeutics to report first quarter 2023 financial results on may 4

WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing ta...

April 11, 2023, 7:00 am

Foghorn therapeutics to present preclinical data from its selective cbp and ep300 protein degrader programs and preclinical data for fhd-286, a potent, selective inhibitor of brg1 and brm, at the 2023

CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a n...

April 10, 2023, 4:05 pm

Gilead (gild) exercises option to license nurix's candidate

Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein de...

March 21, 2023, 4:01 pm

Nurix's (nrix) stock up due to license option exercise by gilead

Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational t...

March 21, 2023, 11:28 am

Nurix's stock rallies on gilead's option

Shares of Nurix Therapeutics Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gilead Sciences Inc. GILD, -3.18% said it exercise...

March 20, 2023, 9:00 am

Nurix: promising early data from this protein degrader company

NRIX announced early data at ASH last year. The company has a couple of major partnerships....

March 19, 2023, 11:39 pm


Search within

Pages Search Results: